Trial Profile

ING117175: a Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir or Efavirenz Each Administered With Two NRTIs in HIV-1-infected Antiretroviral Therapy-naive Adults Starting Treatment for Rifampicin-sensitive Tuberculosis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dolutegravir (Primary) ; Efavirenz; Ethambutol; Isoniazid; Pyrazinamide; Rifampicin
Indications HIV-1 infections
Focus Registrational; Therapeutic Use
Acronyms INSPIRING
Sponsors ViiV Healthcare

23 Sep 2020 Results (n = 42) assessing population pharmacokinetic analysis of Efavirenz in antiretroviral therapy-naive adults, presented at the 2020 American College of Clinical Pharmacology Annual Meeting
15 Apr 2020 Status changed from active, no longer recruiting to completed.
20 Feb 2020 Planned End Date changed from 31 Dec 2019 to 31 Mar 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com